ARDX
NASDAQ HealthcareArdelyx, Inc. - Common Stock
Biotechnology
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
�� 市场数据
| 价格 | $6.45 |
|---|---|
| 成交量 | 3,341,943 |
| 市值 | 1.58B |
| 贝塔系数 | 0.660 |
| RSI（14日） | 83.4 超买 |
| 200日均线 | $5.89 |
| 50日均线 | $6.21 |
| 52周最高 | $8.40 |
| 52周最低 | $3.21 |
| Forward P/E | 12.36 |
| Price / Book | 9.44 |
🎯 投资策略评分
ARDX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (81/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (17/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ARDX in your text
粘贴任何文章、记录或帖子 — 工具将提取 ARDX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.